Immunome (IMNM) Net Margin (2023 - 2025)
Historic Net Margin for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to 1157.61%.
- Immunome's Net Margin rose 5348200.0% to 1157.61% in Q2 2025 from the same period last year, while for Sep 2025 it was 2419.9%, marking a year-over-year increase of 6945600.0%. This contributed to the annual value of 3382.37% for FY2024, which is 26204500.0% down from last year.
- Latest data reveals that Immunome reported Net Margin of 1157.61% as of Q2 2025, which was up 5348200.0% from 1525.5% recorded in Q1 2025.
- Immunome's 5-year Net Margin high stood at 121.88% for Q3 2023, and its period low was 12857.05% during Q1 2024.
- Its 3-year average for Net Margin is 2486.66%, with a median of 1608.96% in 2025.
- As far as peak fluctuations go, Immunome's Net Margin tumbled by -126679200bps in 2024, and later skyrocketed by 113315500bps in 2025.
- Quarter analysis of 3 years shows Immunome's Net Margin stood at 2421.17% in 2023, then dropped by -25bps to 3030.31% in 2024, then skyrocketed by 62bps to 1157.61% in 2025.
- Its last three reported values are 1157.61% in Q2 2025, 1525.5% for Q1 2025, and 3030.31% during Q4 2024.